查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1703280

RNA 療法臨床試驗市場－全球產業規模、佔有率、趨勢、機會及預測（依治療方式、治療階段、治療領域、地區及競爭情形分類，2020 年至 2030 年）

RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Modality, By Phase, By Therapeutic Areas, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球 RNA 治療臨床試驗市值為 28.7 億美元，預計到 2030 年將達到 40.1 億美元，預測期內複合年成長率為 5.73%。

市場概覽
預測期 2026-2030
2024年市場規模 28.7億美元
2030年市場規模 40.1億美元
2025-2030 年複合年成長率 5.73%
成長最快的領域 罕見疾病
最大的市場 北美洲

RNA療法代表了醫學研究的一個前沿領域，透過針對基因表現為治療多種疾病提供了一種變革性的方法。利用信使 RNA (mRNA)、小干擾 RNA (siRNA) 和反義寡核苷酸 (ASO) 等核糖核酸 (RNA) 分子，基於 RNA 的療法提供了一種精準驅動的方法來調節基因活動。這種方法在治療目前缺乏有效治療選擇的遺傳疾病、傳染病、癌症和罕見疾病方面具有重大前景。

與傳統藥物不同，RNA 療法在基因層面發揮作用，從而能夠提供更有針對性和個人化的治療方案。全球臨床試驗的激增反映了 RNA 科學的進步以及 mRNA 疫苗等基於 RNA 的產品的成功開發，這些產品重新定義了醫療保健格局。這些臨床試驗由學術機構、製藥公司和研究組織合作開展，對於在獲得監管部門批准之前評估這些創新療法的安全性和有效性至關重要。

關鍵市場促進因素

RNA技術的加速創新

主要市場挑戰

交付機制的複雜性

主要市場趨勢

推動個人化和精準醫療

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球RNA治療臨床試驗市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按方式（RNA干擾、反義療法、信使RNA、寡核苷酸、非反義、非RNAi）
    • 依階段（第一階段、第二階段、第三階段、第四階段）
    • 依治療領域（罕見疾病、抗感染、抗癌、神經系統、消化/代謝、肌肉骨骼、心血管呼吸、感覺、其他）
    • 按地區（北美、歐洲、亞太、南美、中東和非洲）
    • 按公司分類（2024）
  • 產品市場圖
    • 按方式
    • 按階段
    • 按治療領域
    • 按地區

第6章：北美RNA療法臨床試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲RNA療法臨床試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區RNA治療臨床試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲

第9章：南美RNA療法臨床試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲 RNA 治療臨床試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購
  • 產品開發
  • 最新動態

第 13 章：競爭格局

  • IQVIA Inc.
  • ICON Plc
  • Laboratory Corporation of America Holdings
  • Charles River Laboratories International, Inc.
  • PAREXEL International Corp.
  • Syneos Health
  • Medpace Holdings, Inc.
  • Novotech Inc.
  • PPD Inc.
  • Veristat, LLC.

第 14 章：策略建議

第15章調查會社について,免責事項

簡介目錄
Product Code: 17089

Global RNA Therapy Clinical Trials Market was valued at USD 2.87 billion in 2024 and is projected to reach USD 4.01 billion by 2030, expanding at a CAGR of 5.73% during the forecast period.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.87 Billion
Market Size 2030USD 4.01 Billion
CAGR 2025-20305.73%
Fastest Growing SegmentRare Diseases
Largest MarketNorth America

RNA therapy represents a cutting-edge domain in medical research, offering a transformative approach to treating a wide range of diseases by targeting gene expression. Leveraging ribonucleic acid (RNA) molecules such as messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs), RNA-based therapies provide a precision-driven method to regulate gene activity. This approach holds significant promise in addressing genetic disorders, infectious diseases, cancer, and rare conditions that currently lack effective treatment options.

Unlike conventional pharmaceuticals, RNA therapies operate at the genetic level, enabling more targeted and personalized treatment solutions. The surge in clinical trials globally reflects both advancements in RNA science and the successful development of RNA-based products, such as mRNA vaccines, which have redefined the healthcare landscape. These clinical trials, conducted through collaborations between academic institutions, pharmaceutical companies, and research organizations, are pivotal in evaluating the safety and efficacy of these innovative therapies prior to regulatory approval.

Key Market Drivers

Accelerated Innovation in RNA Technology

The market's growth is largely fueled by rapid technological advancements in RNA science, reshaping the future of medicine and therapeutic development. A critical area of progress is the refinement of RNA synthesis techniques, which now enable the creation of highly specific and efficient RNA molecules customized to target particular genes or disease pathways.

For instance, in May 2022, Moderna and the nonprofit research organization IAVI announced the initiation of Phase I clinical trials for an experimental mRNA-based HIV vaccine (mRNA-1644), with initial screenings in Rwanda and South Africa.

Further innovations in RNA modification have enhanced molecular stability, reducing degradation and improving biodistribution, which extends the therapeutic effect and reduces dosing frequency-key factors in improving patient compliance. Delivery technologies have also evolved significantly, with lipid nanoparticles and polymer-based carriers protecting RNA during systemic circulation and facilitating precise cellular uptake.

Additionally, combination RNA therapies-which integrate multiple RNA modalities or pair RNA treatments with other therapeutic strategies-are under exploration, offering synergistic potential for more comprehensive disease management.

Key Market Challenges

Complexities in Delivery Mechanisms

A major challenge within the RNA therapy clinical trials market is the effective delivery of RNA molecules to specific cells or tissues. Due to their inherent fragility, RNA molecules are susceptible to enzymatic degradation and immune system activation, limiting their therapeutic utility if not adequately protected and directed.

Moreover, RNA molecules typically exhibit short biological half-lives, requiring repeated administrations to maintain therapeutic levels. Efficient delivery systems are essential to ensure therapeutic RNA reaches the intended cellular targets while minimizing systemic exposure and off-target effects.

To overcome these barriers, researchers have developed advanced delivery platforms-most notably lipid nanoparticle formulations-that encapsulate RNA, shielding it from degradation and enhancing cellular uptake. These systems can be engineered for targeted delivery, ensuring better therapeutic outcomes and minimizing toxicity.

However, challenges remain, particularly in achieving consistent delivery across varied patient profiles and disease states, making delivery optimization a key area of ongoing research and development.

Key Market Trends

Advancing Personalized and Precision Medicine

The shift toward personalized and precision medicine is a transformative trend shaping the RNA therapy clinical trials landscape. This approach leverages individual genetic and molecular profiles to tailor therapeutic interventions, significantly improving treatment outcomes and minimizing adverse effects.

In RNA therapy, personalized medicine involves designing RNA-based therapies that target patient-specific mutations or gene expressions. This enables highly focused treatment strategies, especially for rare or complex conditions.

Precision medicine goes a step further by using genetic profiling and advanced diagnostics to predict how patients will respond to specific RNA therapies. This data-driven approach enhances treatment efficacy, optimizes resource allocation in clinical trials, and supports the development of more targeted RNA-based drug candidates.

Key Market Players

IQVIA Inc.

ICON Plc

Laboratory Corporation of America Holdings

Charles River Laboratories International, Inc.

PAREXEL International Corp.

Syneos Health

Medpace Holdings, Inc.

Novotech Inc.

PPD Inc.

Veristat, LLC.

Report Scope:

In this report, the Global RNA Therapy Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

RNA Therapy Clinical Trials Market, By Modality:

RNA interference

Antisense therapy Messenger RNA

Oligonucleotide

Non-antisense

Non-RNAi

RNA Therapy Clinical Trials Market, By Phase:

Phase I

Phase II

Phase III

Phase IV

RNA Therapy Clinical Trials Market, By Therapeutic Area:

Rare Diseases

Anti-infective

Anticancer

Neurological

Alimentary/Metabolic

Musculoskeletal

Cardiovascular Respiratory

Sensory

Others

RNA Therapy Clinical Trials Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Singapore

South America

  • Brazil
  • Argentina
  • Colombia

Middle East & Africa

  • UAE
  • Saudi Arabia
  • South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Therapy Clinical Trials Market.

Available Customizations:

Global RNA Therapy Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Types
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global RNA Therapy Clinical Trials Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Modality (RNA interference, Antisense therapy, Messenger RNA, Oligonucleotide, non-antisense, non-RNAi)
    • 5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
    • 5.2.3. By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others)
    • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.5. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Modality
    • 5.3.2. By Phase
    • 5.3.3. By Therapeutic Areas
    • 5.3.4. By Region

6. North America RNA Therapy Clinical Trials Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Modality
    • 6.2.2. By Phase
    • 6.2.3. By Therapeutic Areas
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States RNA Therapy Clinical Trials Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Modality
        • 6.3.1.2.2. By Phase
        • 6.3.1.2.3. By Therapeutic Areas
    • 6.3.2. Canada RNA Therapy Clinical Trials Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Modality
        • 6.3.2.2.2. By Phase
        • 6.3.2.2.3. By Therapeutic Areas
    • 6.3.3. Mexico RNA Therapy Clinical Trials Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Modality
        • 6.3.3.2.2. By Phase
        • 6.3.3.2.3. By Therapeutic Area

7. Europe RNA Therapy Clinical Trials Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Modality
    • 7.2.2. By Phase
    • 7.2.3. By Therapeutic Area
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany RNA Therapy Clinical Trials Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Modality
        • 7.3.1.2.2. By Phase
        • 7.3.1.2.3. By Therapeutic Area
    • 7.3.2. France RNA Therapy Clinical Trials Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Modality
        • 7.3.2.2.2. By Phase
        • 7.3.2.2.3. By Therapeutic Area
    • 7.3.3. United Kingdom RNA Therapy Clinical Trials Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Modality
        • 7.3.3.2.2. By Phase
        • 7.3.3.2.3. By Therapeutic Area
    • 7.3.4. Italy RNA Therapy Clinical Trials Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Modality
        • 7.3.4.2.2. By Phase
        • 7.3.4.2.3. By Therapeutic Area
    • 7.3.5. Spain RNA Therapy Clinical Trials Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Modality
        • 7.3.5.2.2. By Phase
        • 7.3.5.2.3. By Therapeutic Area

8. Asia-Pacific RNA Therapy Clinical Trials Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Modality
    • 8.2.2. By Phase
    • 8.2.3. By Therapeutic Area
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China RNA Therapy Clinical Trials Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Modality
        • 8.3.1.2.2. By Phase
        • 8.3.1.2.3. By Therapeutic Area
    • 8.3.2. Japan RNA Therapy Clinical Trials Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Modality
        • 8.3.2.2.2. By Phase
        • 8.3.2.2.3. By Therapeutic Area
    • 8.3.3. India RNA Therapy Clinical Trials Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Modality
        • 8.3.3.2.2. By Phase
        • 8.3.3.2.3. By Therapeutic Area
    • 8.3.4. South Korea RNA Therapy Clinical Trials Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Modality
        • 8.3.4.2.2. By Phase
        • 8.3.4.2.3. By Therapeutic Area
    • 8.3.5. Australia RNA Therapy Clinical Trials Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Modality
        • 8.3.5.2.2. By Phase
        • 8.3.5.2.3. By Therapeutic Area

9. South America RNA Therapy Clinical Trials Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Modality
    • 9.2.2. By Phase
    • 9.2.3. By Therapeutic Area
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil RNA Therapy Clinical Trials Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Modality
        • 9.3.1.2.2. By Phase
        • 9.3.1.2.3. By Therapeutic Area
    • 9.3.2. Argentina RNA Therapy Clinical Trials Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Modality
        • 9.3.2.2.2. By Phase
        • 9.3.2.2.3. By Therapeutic Area
    • 9.3.3. Colombia RNA Therapy Clinical Trials Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Modality
        • 9.3.3.2.2. By Phase
        • 9.3.3.2.3. By Therapeutic Area

10. Middle East and Africa RNA Therapy Clinical Trials Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Modality
    • 10.2.2. By Phase
    • 10.2.3. By Therapeutic Area
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE RNA Therapy Clinical Trials Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Modality
        • 10.3.1.2.2. By Phase
        • 10.3.1.2.3. By Therapeutic Area
    • 10.3.2. Saudi Arabia RNA Therapy Clinical Trials Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Modality
        • 10.3.2.2.2. By Phase
        • 10.3.2.2.3. By Therapeutic Area
    • 10.3.3. South Africa RNA Therapy Clinical Trials Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Modality
        • 10.3.3.2.2. By Phase
        • 10.3.3.2.3. By Therapeutic Area

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Competitive Landscape

  • 13.1. IQVIA Inc.
    • 13.1.1. Business Overview
    • 13.1.2. Company Snapshot
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As Reported)
    • 13.1.5. Recent Developments
    • 13.1.6. Key Personnel Details
    • 13.1.7. SWOT Analysis
  • 13.2. ICON Plc
  • 13.3. Laboratory Corporation of America Holdings
  • 13.4. Charles River Laboratories International, Inc.
  • 13.5. PAREXEL International Corp.
  • 13.6. Syneos Health
  • 13.7. Medpace Holdings, Inc.
  • 13.8. Novotech Inc.
  • 13.9. PPD Inc.
  • 13.10. Veristat, LLC.

14. Strategic Recommendations

15. About Us & Disclaimer